New drug duo aims to control Tough-to-Treat breast cancer
Disease control
Ongoing
This study is testing whether combining two targeted drugs, tucatinib and alpelisib, can help control advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The first part checks the safety and best dose of the combination. The second part expa…
Phase: PHASE1, PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC